Manchester Capital Management LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Manchester Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 161 shares of the biopharmaceutical company’s stock after purchasing an additional 18 shares during the period. Manchester Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $115,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. ABC Arbitrage SA acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $1,510,000. Klingenstein Fields & Co. LP raised its stake in Regeneron Pharmaceuticals by 1,083.7% during the 4th quarter. Klingenstein Fields & Co. LP now owns 6,806 shares of the biopharmaceutical company’s stock worth $4,848,000 after acquiring an additional 6,231 shares in the last quarter. Banque Pictet & Cie SA acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $4,496,000. V Square Quantitative Management LLC raised its stake in Regeneron Pharmaceuticals by 11.9% during the 4th quarter. V Square Quantitative Management LLC now owns 1,489 shares of the biopharmaceutical company’s stock worth $1,061,000 after acquiring an additional 158 shares in the last quarter. Finally, Vontobel Holding Ltd. raised its stake in Regeneron Pharmaceuticals by 56.1% during the 4th quarter. Vontobel Holding Ltd. now owns 6,458 shares of the biopharmaceutical company’s stock worth $4,600,000 after acquiring an additional 2,322 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Sanford C. Bernstein dropped their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Citigroup dropped their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Down 0.1 %

REGN stock opened at $673.60 on Friday. The company has a market cap of $74.02 billion, a P/E ratio of 17.60, a P/E/G ratio of 2.38 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company’s 50-day moving average price is $706.92 and its 200 day moving average price is $897.42. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.86 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.